Kerry’s probiotic ingredient supports digestive health in healthy Chinese adults

BC30™ (Heyndrickxia coagulans GBI-30, 6086), a spore-forming probiotic developed by Kerry Group, has been shown to significantly improve gastrointestinal function and digestive health in healthy Chinese adults with irregular bowel movements, according to a newly published clinical study.

The randomized, double-blind, placebo-controlled trial was conducted at the Beijing Institute of Geriatrics, Beijing Hospital, National Health Commission, China. Over a 28-day period, 111 healthy adults aged 18–65 consumed 1 billion CFU/day of BC30™ in a ready-to-mix nutritional sachet rehydrated in a beverage. Prior to the study, participants reported irregular bowel movements, defined as four or fewer bowel movements per week or two or more loose stools per week.

(Photo courtesy of Kerry)

Key findings:

• Improved Digestive Function: Participants consuming BC30™ experienced a statistically significant increase in stool frequency and improved fecal consistency.
•  
• Symptom Relief: Significant improvements were observed in overall GSRS (Gastrointestinal Symptom Rating Scale) scores, particularly in abdominal pain and constipation, during the final two weeks of the study.
•  
• Microbiome Modulation: BC30™ intake led to increased levels of Bacteroides spp. and decreased levels of Clostridium spp., indicating positive modulation of the gut microbiota.
•  
• Well-Tolerated: No adverse effects were reported, confirming BC30™’s safety and tolerability.

This study marks the first clinical validation of BC30™ in an Asian population, expanding the global relevance of its digestive health benefits. The trial was registered at ClinicalTrials.gov (NCT06644001) and published in Beneficial Microbes.¹
 

“BC30™ continues to demonstrate its versatility and efficacy across diverse populations,” said Dr. Mathieu Millette, RDA Director, Digestive Health, Kerry. “This study reinforces our commitment to delivering clinically substantiated ingredients that support real consumer needs.”
 

With over 65 published studies, BC30™ is recognised for its stability, safety, and efficacy in digestive health and protein utilization. It is U.S. FDA-notified GRAS and accepted by regulatory bodies globally.

BC30™ is part of Kerry’s portfolio of science-backed solutions tailored to meet digestive health needs of consumers around the world.

----

¹Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/40707016/